Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease

Sophie Restellini, Waqqas Afif, Sophie Restellini, Waqqas Afif

Abstract

The goal of therapeutic drug monitoring (TDM) is to optimize anti-TNF (tumor necrosis factor) biologic treatment in patients with inflammatory bowel disease (IBD). Although commercial assays are readily available for both ustekinumab and vedolizumab, the use of TDM with these newer biologic medications is at its infancy. The clinical utility of TDM with non-anti-TNF mechanisms of action is not clear. This review summarizes the latest available data on the pharmacokinetics of newer biologic and oral small molecules and highlights the threshold concentrations that have been associated with improved outcomes in IBD patients.

Keywords: biologic; therapeutic drug monitoring; tofacitinib; ustekinumab; vedolizumab.

Conflict of interest statement

S.R. has no conflicts of interest. W.A. received consultancy fees from Abbvie, Amgen, Arena Pharmaceuticals, Dynacare, Janssen, Merck, Novartis, Pfizer, Sandoz, Takeda.

References

    1. Reinglas J., Gonczi L., Kurt Z., Bessissow T., Lakatos P.L. Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases. World J. Gastroenterol. 2018;24:3567–3582. doi: 10.3748/wjg.v24.i32.3567.
    1. Feagan B.G., Rutgeerts P., Sands B.E., Hanauer S., Colombel J.-F., Sandborn W.J., Van Assche G., Axler J., Kim H.-J., Danese S., et al. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N. Engl. J. Med. 2013;369:699–710. doi: 10.1056/NEJMoa1215734.
    1. Sandborn W.J., Feagan B.G., Rutgeerts P., Hanauer S., Colombel J.-F., Sands B.E., Lukas M., Fedorak R.N., Lee S., Bressler B., et al. Vedolizumab as Induction and Maintenance Therapy for Crohn’s Disease. N. Engl. J. Med. 2013;369:711–721. doi: 10.1056/NEJMoa1215739.
    1. Sands B.E., Feagan B.G., Rutgeerts P., Colombel J.-F., Sandborn W.J., Sy R., D’Haens G., Ben-Horin S., Xu J., Rosario M., et al. Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed. Gastroenterology. 2014;147:618–627.e3. doi: 10.1053/j.gastro.2014.05.008.
    1. Feagan B.G., Sandborn W.J., Gasink C., Jacobstein D., Lang Y., Friedman J.R., Blank M.A., Johanns J., Gao L.-L., Miao Y., et al. Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease. N. Engl. J. Med. 2016;375:1946–1960. doi: 10.1056/NEJMoa1602773.
    1. Sands B.E., Sandborn W.J., Panaccione R., O’Brien C.D., Zhang H., Johanns J., Adedokun O.J., Li K., Peyrin-Biroulet L., Van Assche G., et al. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N. Engl. J. Med. 2019;381:1201–1214. doi: 10.1056/NEJMoa1900750.
    1. Salas A., Hernandez-Rocha C., Duijvestein M., Faubion W., McGovern D., Vermeire S., Vetrano S., Casteele N.V. JAK–STAT pathway targeting for the treatment of inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 2020;17:323–337. doi: 10.1038/s41575-020-0273-0.
    1. Ben-Horin S., Mao R., Chen M. Optimizing biologic treatment in IBD: Objective measures, but when, how and how often? BMC Gastroenterol. 2015;15:178. doi: 10.1186/s12876-015-0408-x.
    1. Yanai H., Hanauer S.B. Assessing response and loss of response to biological therapies in IBD. Am. J. Gastroenterol. 2011;106:685–698. doi: 10.1038/ajg.2011.103.
    1. Papamichael K., Cheifetz A.S., Melmed G.Y., Irving P.M., Casteele N.V., Kozuch P.L., Raffals L.E., Baidoo L., Bressler B., Devlin S.M., et al. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clin. Gastroenterol. Hepatol. 2019;17:1655–1668.e3. doi: 10.1016/j.cgh.2019.03.037.
    1. Vermeire S., Dreesen E., Papamichael K., Dubinsky M.C. How, When, and for Whom Should We Perform Therapeutic Drug Monitoring? Clin. Gastroenterol. Hepatol. 2019;18:1291–1299. doi: 10.1016/j.cgh.2019.09.041.
    1. Mitrev N., Casteele N.V., Seow C.H., Andrews J.M., Connor S.J., Moore G.T., Barclay M., Begun J., Bryant R., Chan W., et al. Review article: Consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment. Pharmacol. Ther. 2017;46:1037–1053. doi: 10.1111/apt.14368.
    1. Heron V., Afif W. Update on Therapeutic Drug Monitoring in Crohn’s Disease. Gastroenterol. Clin. N. Am. 2017;46:645–659. doi: 10.1016/j.gtc.2017.05.014.
    1. Feuerstein J.D., Nguyen G.C., Kupfer S.S., Falck-Ytter Y., Singh S. American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Gastroenterology. 2017;153:827–834. doi: 10.1053/j.gastro.2017.07.032.
    1. Afif W., Loftus E.V., A Faubion W., Kane S.V., Bruining D.H., A Hanson K., Sandborn W.J. Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease. Am. J. Gastroenterol. 2010;105:1133–1139. doi: 10.1038/ajg.2010.9.
    1. Kopylov U., Ben-Horin S., Seidman E. Therapeutic drug monitoring in inflammatory bowel disease. Ann. Gastroenterol. 2014;27:304–312.
    1. Restellini S., Khanna R., Afif W. Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease. Inflamm. Bowel Dis. 2018;24:2165–2172. doi: 10.1093/ibd/izy134.
    1. Engel T., Kopylov U. Ustekinumab in Crohn’s disease: Evidence to date and place in therapy. Ther. Adv. Chronic Dis. 2016;7:208–214. doi: 10.1177/2040622316653306.
    1. STELARA ® (Ustekinumab) Injection, for Subcutaneous or Intravenous Use. Initial U.S. Approval: 2009. [(accessed on 14 November 2020)]; Available online: .
    1. Gottlieb A.B., Cooper K.D., McCormick T.S., Toichi E., Everitt D.E., Frederick B., Zhu Y., Pendley C.E., Graham M.A., Mascelli M.A. A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr. Med Res. Opin. 2007;23:1081–1092. doi: 10.1185/030079907X182112.
    1. Young A., Tsistrakis S., Rubinov J. Ustekinumab Dose Intensification Can Be Effective in Crohn’s Disease Patients Not Responding to Induction. Am. J. Gastroenterol. 2018;113:S351–S352. doi: 10.14309/00000434-201810001-00617.
    1. Ustekinumab UCfDEaR. [(accessed on 10 April 2020)]; Available online: .
    1. Wang W., Wang E.Q., Balthasar J.P. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 2008;84:548–558. doi: 10.1038/clpt.2008.170.
    1. Lamb Y.N., Duggan S.T. Ustekinumab: A Review in Moderate to Severe Crohn’s Disease. Drugs. 2017;77:1105–1114. doi: 10.1007/s40265-017-0765-6.
    1. Adedokun O.J., Xu Z., Gasink C., Jacobstein D., Szapary P., Johanns J., Gao L.-L., Davis H.M., Hanauer S.B., Feagan B.G., et al. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn’s Disease. Gastroenterology. 2018;154:1660–1671. doi: 10.1053/j.gastro.2018.01.043.
    1. Adedokun O., Xu Z.H., Gasink C., Jacobstein D., Szapary P., Johanns J., Gao L.-L., Davis H., Hanauer S., Feagan B., et al. Exposure-Response to SC Ustekinumab in Moderate –Severe Crohn’s Disease: Results From the IM-UNITI Maintenance Study. Am. J. Gastroenterol. 2018;113:pS2.
    1. Alsoud D., Vermeire S., Verstockt B. Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: Hype or hope? Curr. Opin. Pharmacol. 2020;55:17–30. doi: 10.1016/j.coph.2020.09.002.
    1. Sandborn W., Gasink C., Lang Y., Johanns J., Gao L.-L., Sands B., Hanauer S., Feagan B., Targan S., De Villiers W., et al. O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohn’s Disease Refractory to Anti-TFNα. Inflamm. Bowel Dis. 2016;22:S1. doi: 10.1097/MIB.0000000000000720.
    1. Hanzel J., Zdovc J., Kurent T., Sever N., Javornik K., Tuta K., Koželj M., Smrekar N., Novak G., Štabuc B., et al. Peak Concentrations of Ustekinumab after Intravenous Induction Therapy Identify Patients with Crohn’s Disease Likely to Achieve Endoscopic and Biochemical Remission. Clin. Gastroenterol. Hepatol. 2020;19:111–118.e10. doi: 10.1016/j.cgh.2020.02.033.
    1. Battat R., Kopylov U., Bessissow T., Bitton A., Cohen A., Martel M., Seidman E.G., Afif W. 696 Association of Ustekinumab Trough Concentrations With Clinical, Biochemical and Endoscopic Outcomes. Gastroenterology. 2016;150:S144–S145. doi: 10.1016/S0016-5085(16)30587-X.
    1. Painchart C., Brabant S., Duveau N., Nachury M., Desreumaux P., Branche J., Gérard R., Prevost C.L.D., Wils P., Lambin T., et al. Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn’s Disease. Dig. Dis. Sci. 2019;65:1445–1452. doi: 10.1007/s10620-019-05865-3.
    1. Verdon C., Vande Casteele N., Heron V. Comparison of Serum Concentrations of Ustekinumab Obtained by Three Commercial Assays in Patients with Crohn’s Disease. J. Can. Assoc. Gastroenterol. 2020;XX:1–5. doi: 10.1093/jcag/gwaa003.
    1. Adedokun O.J., Xu Z., Marano C., O’Brien C., Szapary P., Zhang H., Johanns J., Leong R.W., Hisamatsu T., Van Assche G., et al. Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients with Ulcerative Colitis: Ustekinumab PK and exposure-response in UC. Clin. Gastroenterol. Hepatol. 2019;18:2244–2255.e9. doi: 10.1016/j.cgh.2019.11.059.
    1. Adedokun O., Panaccione R., Hisamatsu T., Abreu M.T., Leong R.W.L., Rowbotham D., Marano C., Zhou Y., Zhang H., Danese S., et al. S0845 Pharmacokinetics and Immunogenicity of Maintenance Therapy With Ustekinumab: 2-Year Results From the UNIFI Long-Term Extension Study. Am. J. Gastroenterol. 2020;115:S437. doi: 10.14309/.
    1. D’Haens G., Adedokun O.J. Pharmacokinetics, immunogenicity, and exposure-response relationship of ustekinumab in patients with crohn’s disease: Results from the week 16 interim analysis of the stardust study. Gastroenterology. 2020;154:1660–1667.
    1. Kopylov U., Afif W., Cohen A., Bitton A., Wild G., Bessissow T., Wyse J., Al-Taweel T., Szilagyi A., Seidman E. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn’s disease—The McGill experience. J. Crohn’s Coliti. 2014;8:1516–1522. doi: 10.1016/j.crohns.2014.06.005.
    1. Heron V., Bessissow T., Bitton A., Lakatos P.L., Seidman E.G., Jain A., Battat R., Germain P., Lemieux C., Afif W. Tu1825—Ustekinumab Therapeutic Drug Monitoring in Crohn’s Disease Patients with Loss of Response. Gastroenterology. 2019;156:S-1139. doi: 10.1016/S0016-5085(19)39811-7.
    1. Fumery M., Peyrin-Biroulet L., Nancey S., Altwegg R., Veyrard P., Bouguen G., Viennot S., Poullenot F., Filippi J., Buisson A., et al. OP24 Effectiveness and safety of ustekinumab 90 mg every 4 weeks in Crohn’s disease. J. Crohn’s Coliti. 2019;13:S016. doi: 10.1093/ecco-jcc/jjy222.023.
    1. Fumery M., Peyrin-Biroulet L., Nancey S., Altwegg R., Gilletta C., Veyrard P., Bouguen G., Viennot S., Poullenot F., Filippi J., et al. Effectiveness and Safety of Ustekinumab Intensification at 90 mg Every 4 Weeks in Crohn’s Disease: A Multicentre Study. J. Crohn’s Coliti. 2021;15:222–227. doi: 10.1093/ecco-jcc/jjaa177.
    1. Heron V., Panaccione R., Candido K. Efficacy of Intravenous Ustekinumab Re-Induction in Patients with Crohn’s Disease with a Loss of Response. Gastroenterology. 2019;156:S347–S348.
    1. Battat R., Kopylov U., Bessissow T., Bitton A., Cohen A., Jain A., Martel M., Seidman E., Afif W. Association between Ustekinumab trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients with Crohn’s Disease. Clin. Gastroenterol. Hepatol. 2017;15:1427–1434.e2. doi: 10.1016/j.cgh.2017.03.032.
    1. Hu A., Kotze P.G., Burgevin A., Tan W., Jess A., Li P.-S., Kroeker K., Halloran B., Panaccione R., Peyrin-Biroulet L., et al. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab. Clin. Gastroenterol. Hepatol. 2020 doi: 10.1016/j.cgh.2020.07.012.
    1. Yzet C., Diouf M., Singh S., Brazier F., Turpin J., Nguyen-Khac E., Meynier J., Fumery M. No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients with Inflammatory Bowel Diseases: A Meta-analysis. Clin. Gastroenterol. Hepatol. 2020 doi: 10.1016/j.cgh.2020.06.071.
    1. Sandborn W.J., Gasink C., Gao L.-L., Blank M.A., Johanns J., Guzzo C., Sands B.E., Hanauer S.B., Targan S., Rutgeerts P., et al. Ustekinumab Induction and Maintenance Therapy in Refractory Crohn’s Disease. N. Engl. J. Med. 2012;367:1519–1528. doi: 10.1056/NEJMoa1203572.
    1. Chaparro M., Guerra I., Munoz-Linares P., Gisbert J.P. Systematic review: Antibodies and anti-TNF-alpha levels in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2012;35:971–986. doi: 10.1111/j.1365-2036.2012.05057.x.
    1. Sandborn W.J., Baert F., Danese S., Krznarić Ž., Kobayashi T., Yao X., Chen J., Rosario M., Bhatia S., Kisfalvi K. Efficacy and safety of vedolizumab SC in patients with moderately to severely active Crohn’s disease: Results of the VISIBLE 2 study. J. Crohn’s Colitis. 2020;14:S020–S021.
    1. Sandborn W.J., Baert F., Danese S., Krznarić Ž., Kobayashi T., Yao X., Chen J., Rosario M., Bhatia S., Kisfalvi K., et al. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2020;158:562–572.e12. doi: 10.1053/j.gastro.2019.08.027.
    1. Soler D., Chapman T., Yang L.L., Wyant T., Egan R., Fedyk E.R. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J. Pharmacol. Exp. Ther. 2009;330:864–875. doi: 10.1124/jpet.109.153973.
    1. Rosario M., Dirks N.L., Gastonguay M.R., Fasanmade A.A., Wyant T., Parikh A., Sandborn W.J., Feagan B.G., Reinisch W., Fox I., et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn’s disease. Aliment. Pharmacol. Ther. 2015;42:188–202. doi: 10.1111/apt.13243.
    1. Bryant R.V., Sandborn W.J., Travis S.P. Introducing vedolizumab to clinical practice: Who, when, and how? J. Crohn’s Colitis. 2015;9:356–366. doi: 10.1093/ecco-jcc/jjv033.
    1. Rosario M., Dirks N.L., Milch C., Parikh A., Bargfrede M., Wyant T., Fedyk E., Fox I. A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab. Clin. Pharmacokinet. 2017;56:1287–1301. doi: 10.1007/s40262-017-0546-0.
    1. Ward M.G., Sparrow M.P., Roblin X. Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: Current data and future directions. Ther. Adv. Gastroenterol. 2018;11 doi: 10.1177/1756284818772786.
    1. Parikh A., Leach T., Wyant T., Scholz C., Sankoh S., Mould D.R., Ponich T., Fox I., Feagan B.G. Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study. Inflamm. Bowel Dis. 2012;18:1470–1479. doi: 10.1002/ibd.21896.
    1. Becker E., Wiendl M., Schulz-Kuhnt A., Atreya I., Atreya R., Neurath M., Zundler S. P062 Dose-dependent differential effects of vedolizumab therapy on adhesion of regulatory and effector T cells. J. Crohn’s Coliti. 2020;14:S165–S166. doi: 10.1093/ecco-jcc/jjz203.191.
    1. Pouillon L., Vermeire S., Bossuyt P. Vedolizumab trough level monitoring in inflammatory bowel disease: A state-of-the-art overview. BMC Med. 2019;17:89. doi: 10.1186/s12916-019-1323-8.
    1. Rosario M., French J.L., Dirks N.L., Sankoh S., Parikh A., Yang H., Danese S., Colombel J.-F., Smyth M., Sandborn W.J., et al. Exposure–efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s Disease. J. Crohn’s Coliti. 2017;11:921–929. doi: 10.1093/ecco-jcc/jjx021.
    1. Boland B.S., Dulai P., Jain A. Association of vedolizumab concentrations using PROMETHEUS® Anser® VDZ mobility shift assay and clinical response in IBD patients in standard clinical practice; Proceedings of the American College of Gastroenterology Scientific Meeting; Las Vegas, NV, USA. 14–19 October 2016.
    1. Osterman M.T., Roblin X., Glover S.C., Navaneethan U., Popa M.A., Wyant T., James A., Lasch K., Rosario M. 512 Association of Vedolizumab Drug Concentrations at or Before Week 6 With Remission at Week 14 in Moderately to Severely Active Ulcerative Colitis Patients From GEMINI 1. Gastroenterology. 2016;150:S105. doi: 10.1016/S0016-5085(16)30458-9.
    1. Paul S., Williet N., Claudez P., Fauvet M., Del Tedesco E., Jarlot C., Phelip J.M., Genin C., Depince A., Roblin X. Sa1939 Serum Vedolizumab Assay at Week 6 Predicts Sustained Clinical Remission and Lack of Recourse to Optimisation in IBD. Gastroenterology. 2016;150:S410. doi: 10.1016/S0016-5085(16)31427-5.
    1. Williet N., Paul S., Del Tedesco E., Phelip J.M., Roblin X. P632 Serum vedolizumab assay at week 6 predicts sustained clinical remission and lack of recourse to optimisation in inflammatory bowel disease DDW abstract Sa1939. Gastroenterology. 2016;150(Suppl. S1):S410.
    1. Williet N., Boschetti G., Fovet M., Di Bernado T., Claudez P., Del Tedesco E., Jarlot C., Rinaldi L., Berger A., Phelip J.-M., et al. Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months. Clin. Gastroenterol. Hepatol. 2017;15:1750–1757.e3. doi: 10.1016/j.cgh.2016.11.023.
    1. Dreesen E., Verstockt B., Bian S., de Bruyn M., Compernolle G., Tops S., Noman M., Van Assche G., Ferrante M., Gils A., et al. Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases. Clin. Gastroenterol. Hepatol. 2018;16:1937–1946.e8. doi: 10.1016/j.cgh.2018.04.040.
    1. Verstockt B., Mertens E., Dreesen E., Outtier A., Noman M., Tops S., Schops G., Van Assche G., Vermeire S., Gils A., et al. Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients. J. Crohn’s Coliti. 2019;14:332–341. doi: 10.1093/ecco-jcc/jjz151.
    1. Vande Casteele N., Sandborn W.B.G.F. Real-world exposure-response relationship of vedolizumab in inflammatory bowel disease: A pooled multicentre observational cohort analysis of clinical and modeled pharmacological data. UEG J. 2020;8:144–887. doi: 10.14309/01.ajg.0000704656.65634.c9.
    1. Yarur A.J., Bruss A., Jain A., Kondragunta V., Luna T.L., Hester K., Patel A., Agrawal D., Fox C., Werner S., et al. Higher Vedolizumab Levels are Associated with Deep Remission in Patients with Crohn’s Disease and Ulcerative Colitis on Maintenance Therapy with Vedolizumab. Gastroenterology. 2017;152:S389. doi: 10.1016/S0016-5085(17)31541-X.
    1. Ungaro R., Jossen J., Phan B., Chefitz E., Jain A., Naik S., Dubinsky M. Higher Vedolizumab Trough Levels Associated with Remission in Inflammatory Bowel Disease (IBD) Patients during Maintenance Therapy. Inflamm. Bowel Dis. 2017;23:S7. doi: 10.1097/01.MIB.0000512530.93619.36.
    1. Ungaro R.C., Yarur A., Jossen J., Phan B.L., Chefitz E., Sehgal P., Kamal K., Bruss A., Beniwal-Patel P., Fox C., et al. Higher Trough Vedolizumab Concentrations during Maintenance Therapy are Associated with Corticosteroid-Free Remission in Inflammatory Bowel Disease. J. Crohn’s Colitis. 2019;13:963–969. doi: 10.1093/ecco-jcc/jjz041.
    1. Vermeire S., Loftus E.V., Colombel J.-F., Feagan B.G., Sandborn W.J., Sands B.E., Danese S., D’Haens G.R., Kaser A., Panaccione R., et al. Long-term Efficacy of Vedolizumab for Crohn’s Disease. J. Crohn’s Coliti. 2016;11:412–424. doi: 10.1093/ecco-jcc/jjw176.
    1. Peyrin-Biroulet L., Danese S., Argollo M., Pouillon L., Peppas S., Gonzalez-Lorenzo M., Lytras T., Bonovas S. Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn’s Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis. Clin. Gastroenterol. Hepatol. 2019;17:838–846.e832. doi: 10.1016/j.cgh.2018.06.026.
    1. Outtier A., Rahier J., Bossuyt P. Effect of vedolizumab dose intensification on serum drug concentrations and regain of response in inflammatory bowel disease patients with secondary loss of response. GastroHep. 2019 doi: 10.1002/ygh2.444.
    1. Raine T. Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same? United Eur. Gastroenterol. J. 2014;2:333–344. doi: 10.1177/2050640614550672.
    1. Rosario M., Wyant T., Milch C., Parikh A., Feagan B., Sandborn W.J., Yang H., Fox I. DOP058. Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies. J. Crohn’s Colitis. 2014;8(Suppl. S1):30–31. doi: 10.1016/S1873-9946(14)60083-0.
    1. Sandborn W.J., Su C., Sands B.E., D’Haens G.R., Vermeire S., Schreiber S., Danese S., Feagan B.G., Reinisch W., Niezychowski W., et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N. Engl. J. Med. 2017;376:1723–1736. doi: 10.1056/NEJMoa1606910.
    1. Sandborn W.J., Ghosh S., Panes J., Vranic I., Su C., Rousell S., Niezychowski W. Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis. N. Engl. J. Med. 2012;367:616–624. doi: 10.1056/NEJMoa1112168.
    1. Hutmacher M., Papp K., Krishnaswami S., Ito K., Tan H., Wolk R., Valdez H., Mebus C., Rottinghaus S., Gupta P. Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight. CPT Pharmacomet. Syst. Pharmacol. 2017;6:322–330. doi: 10.1002/psp4.12182.
    1. Mukherjee A., Hazra A., Smith M.K., Martin S.W., Mould D.R., Su C., Niezychowski W. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial. Br. J. Clin. Pharmacol. 2018;84:1136–1145. doi: 10.1111/bcp.13523.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren